Gaithersburg-based Novavax Inc. — known for its work developing vaccine candidates for the flu, a pediatric respiratory illness and Ebola — expanded into a new 54,000-square-foot research and development space where it plans to house its vaccine work.
“It’s a very important signal of our continued growth,” said Buck Phillips, chief financial officer of Novavax (Nasdaq: NVAX) of the new space at 21 Firstfield Road, across the street from its headquarters.
{iframe}http://www.bizjournals.com/washington/blog/2015/06/gaithersburg-biotech-expands-into-new-research.html{/iframe}